As a senior expert in monoclonal antibodies production and development, Creative Biolabs has established a special and professional Non-IgG Antibody Expression Systems based on our seasoned IgG isotype monoclonal antibody technologies and platforms.
Due to the limited availability of living human brain tissue, the development in elucidating the molecular and cellular pathophysiology of neuropsychiatric disorders has been hindered impeded. However, the discovery of iPSCs has offered the opportunity to study the physiology of living human neurons derived from individual patients. Learn more: stem cell differentiation
Isolation of ribosomal particles is critical for studying ribosomal composition and for analyzing factors that interact with ribosomes. As a reputable global service provider, Creative Biolabs has extensive experience in ribosome extraction and isolation experiments. We provide cost-effective services according to the different needs of customers. Learn more: Ribosome Separation and Extraction Services
Recombinant Anti-Ad fiber knob x Anti-CEA Bispecific Antibody (Triple Body) is designed to be expressed as two polypeptide chains respectively. The Fd fragment and LC from an anti-Ad fiber knob antibody are both extended with the scFv fragment from an anti-CEA antibody. Learn more: Ad fiber knob CEA Triple Body
Direct-targeting monoclonal antibodies (mAbs) approved for usage in oncology mainly belong to the immunoglobulin (Ig) G class currently. In fact, non-IgG therapeutic antibodies come of age with major progress in different kinds of human diseases, such as cancers and chronic inflammation. IgG mAb is no longer the only player in the therapeutic fields owing to antibody engineering technique, which is further driving the development of novel antibody formats. Besides, genetically modified cell-based therapies that harness the power of the immune system, together with non-IgG therapeutic antibodies, have improved cures in intractable human diseases. Learn more: IgE antibody engineering
Previous reports have provided an excellent starting point for larger prospective studies of the clinical utility of circulating tumor DNA (ctDNA) and demonstrate that ctDNA may be a useful research tool for drug development, and the study of intratumor heterogeneity and clonal evolution. As a biotechnology company standing at the forefront of the industry, Creative Biolabs is proficient in advanced technologies and the latest methods. We are confident in offering high-quality and comprehensive ctdna detection services.
The adenosine A2A receptor (A2AR) belongs to the G protein-coupled receptor (GPCR) family A or rhodopsin receptor family. Adenosine receptors include four subtypes (A1R, A2AR, A2BR, and A3R) that are activated by extracellular adenosine. A2AR and A1R are widely distributed throughout the central nervous system and surrounding, while low-density A2BR and A3R are present in the brain. Learn more: Next-IO™ A2AR Therapeutic Monoclonal Antibody Program
With years of hard working in exosome technology and engineering, Creative Biolabs has got all the necessary knowledge and technologies of exosomes. We give an introduction of the therapeutic applications of exosomes in diseases and approaches utilized for drug loading into exosomes. Learn more: exosome therapy
In order to understand human processes and behaviors, mammalian models provide the greatest insights because they share a high degree of homology with human. As it is easy to store, mouse and rat are the most important representatives. Learn more: guinea pig antibody
Point-of-care technology (POCT) diagnostic systems are tools that can rapidly lead to in vitro diagnostic (IVD) results by non-trained personnel at a patient site in varieties of locations such as the field, the home, the ambulance, or the hospital. To this day, diagnostic tests are typically operated at laboratories equipped with bench-top analyzers and managed by trained personnel. Learn more: microfluidic rapid detection
Monoclonal antibodies are versatile tools against numerous diseases ranging from cancers to series of infectious, immunological, or chronic diseases. Their high affinity and specificity towards corresponding antigens make them excellent molecular trackers for the targets in the form of antibody-based probes. Besides the expertise in antibody design and engineering, Creative Biolabs is also dedicated to the areas of high-resolution imagery, molecular tracking, and cancer diagnostics by developing customized Antibody-based Probes via the conjugation of monoclonal antibodies with various biophysical probes. Learn more: antibody labeling
This gene encodes a lysosomal protein which hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Mutations in this gene have been associated with Krabbe disease, also known as globoid cell leukodystrophy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. Learn more: galc antibody
Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of AI-augmented drug discovery solutions for worldwide customers. We are proud to partner with our clients on the journey of bringing novel antibody candidates to market. Learn more: antibody ai
As an incontrovertible leader in antibodies research and development, Creative Biolabs has been recognized as the leader in terms of antibody services providing. After years of foundational effort, our scientific team now provides a series of high-quality non-IgG therapeutic antibodies products and services to our valued customers. Learn more: non-IgG therapeutic antibodies for Pancreas Carcinoma
Exosomes are 30-150 nm tiny vesicles that are available to isolate and purify from plasma and other body fluids and regarded as the useful biomarker for therapeutic and diagnostic application. With years of experiences in exosome preparation, Creative Biolabs provides high-quality exosome purification services by using ultracentrifugation and microfiltration from both plasma and other body fluids with decreased co-purification of non-exosomal blood proteins, thus increasing the purification and integrity of exosomes. Learn more: exosome ultracentrifugation
Syngeneic mice-derived models could recapitulate the original disease significantly better than traditional in vitro immortalized cell line derived syngeneic models. Creative Biolabs has established dozens of syngeneic mice-derived preclinical tumor models for studying how cancer therapies perform in the presence of a functional immune system. Our models have been validated by immunohistochemistry and RNAseq, and the gene expression and mutation characteristics were confirmed. We also offer the immunological oncology analysis and immunotherapy efficacy data. Learn more: syngeneic mouse model
Plasma Glycoprotein Profiling is one of the main resources for the identification of glycoprotein biomarkers. As a leading custom service provider, Creative Biolabs has accumulated years of experience in glycoprotein profiling. Based on our first-in-class technology platforms and professional teams, we are proud to share our extensive experience with our customers all over the world in plasma glycoprotein profiling. We can offer high-quality customized services by adjusting protocols to meet even the most specific requirements.
Creative Biolabs stands out in the field of infectious disease treatment research services with its comprehensive advantages, becoming a highly trusted partner for clients. Learn more: anti parasit
Anti-glycan antibodies are antibodies to specific glycan epitopes and thus can bind specifically to glycoproteins containing these determinants. Due to the specificity of anti-glycan antibodies, they are used as essential tools for basic research. Here, Creative Biolabs gives an introduction to the application of anti-glycan antibodies in glycan/glycoprotein purification. Learn more: Glycan Antibody for Glycan Purification
As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in our antibody design services. Learn more: bioconjugation services